Pharmacists have a role in managing anticoagulant therapy in acutely ill hospitalized patients at risk for VTE, including protocol development and research, identifying an unmet need and the value of prophylaxis in medically ill patients, and implementing practical DVT and PE prevention strategies. Consensus guidelines (e.g., COVID-19 ISTH 2020, COVID-19 ACC) have provided some guidance for COVID-19 infection and the connection to deep vein thrombosis and pulmonary embolism.
SPEAKERS
John Fanikos, R.Ph., M.B.A., is Chief of Pharmacy Services at Brigham and Women's Hospital (BWH) in Boston, Massachusetts. Mr. Fanikos is responsible for the overall Pharmacy Department operations. As part of his research interests, he has worked closely with the BWH Thromboembolism Research Group for over 25 years. He has authored and co-authored over 100 peer reviewed articles and textbook chapters on medication use with a specific emphasis on optimizing medication utilization. His research focus has been identifying and avoiding the problems and pitfalls of medication use.
Relevant Financial Relationship Disclosure with an Ineligible Company*
- Consultant, Pfizer
- Consultant, Pacira
- Consultant, Boehringer-Ingelheim
- Consultant, Allergan
- Consultant, Alexion
All of the relevant financial relationships have been mitigated.
*As defined by the Standards of Integrity and Independence definition of ineligible company.
George Davis, Pharm.D., is Antithrombosis Stewardship Program Coordinator at UK HealthCare Pharmacy Services and Adjunct Professor with University of Kentucky College of Pharmacy. In his current position, he is lead pharmacist of the UK HealthCare Anticoagulation Stewardship Program that includes involvement in a multidisciplinary antithrombosis consult service, quality assurance/safety, and formulary management of antithrombotics.
Dr. Davis completed his pharmacy residency and research fellowship training at the University of Kentucky and has been a clinical pharmacist at UK HealthCare for over 25 years with practice, teaching, research, and scholarly activity focused in clinical pharmacokinetics and antithrombosis pharmacotherapeutics.
Relevant Financial Relationship Disclosure with an Ineligible Company*
No relevant financial relationship with an ineligible company.
*As defined by the Standards of Integrity and Independence definition of ineligible company.
All others in control of the content of this activity do not have a relevant financial relationship (RFR) with an ineligible company.
This podcast is provided by ASHP and sponsored by Janssen Pharmaceuticals, Inc.
